1994 Fiscal Year Final Research Report Summary
Shortening of lifespan, responsible diseases and difference between Japan and Europe in Thorotrast patients.
| Project/Area Number |
05305002
|
|---|
| Research Category |
Grant-in-Aid for Co-operative Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
広領域
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
MACHINAMI Rikuo Professor, Faculty of Medicine, Univ.of Tokyo, 医学部(医), 教授 (30010052)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIKAWA Yuichi Senior Researcher, Cancer Institue, Dept.of Pathology, 病理部, 研究員 (80222975)
MORI Takesaburo Special Researcher, National Institute of Radiological Sciences, 特別研究員 (00124248)
WATARI Kazuo Special Researcher, National Institute of Radiological Sciences, 特別研究員 (70167196)
KOJIRO Masamichi Professor, Faculty of Medicine, Kurume Univ., 医学部, 教授 (90080580)
|
|---|
| Project Period (FY) |
1993 – 1994
|
| Keywords | Thorotrast / Epidemiology / Histopathology / Lifespan / Malignant liver tumor / Activation analysis / Arsenazo III / War wounded soldiers |
|---|
| Research Abstract |
Epidemiological study has been performed on 258 cases of Thorotrast patients in December 1992 at 46 to 61 years after Thorotrast injection. These 258 cases of Thorotrast patients were all war wounded soldiers and intravascular Thorotrast injection was carried out at the age of 20 to 39. A control study was also done for 1,630 cases of similar war wounded soldiers without Thorotrast injection.
The lifespans of the Thorotast patients were shorter than that of conrtol cases and this difference was increasing year by year. The incidences of malignant liver tumors, liver cirrhosis and blood diseases, and gallbladder cancer were significantly higher in Thorotrast patients than in control cases. It has been well known that Thorotrast is deposited in the liver, spleen, bone marrow and lymph nodes. We examined the deposits of Thorotast in other organs by activation analysis demonstrating the deposits in the testis, adrenal, gallbladder, lung and spleen.
A method for the colorimetric determination of thorium content using Arsenazo III in Thorotrast patient's organs was examined for its usefulness. The experimental values were compared with those obtained by radiation measurement or neutron activation analysis of patient's organs confirming usefulness of this method.
Nine cases of Thorotrast associated hepatocellular carcinoma (HCC) and 14 cases of non-Thorotrast associated HCC were examined on the presence of victoria blue positive hepatocytes and p53 positive carcinoma cells. Neither victoria blue positive hepatocytes nor p53 positive carcinoma cells were found in Thorotrast associated HCC,whereas 2 of 14 cases of non-Thorotrast associated HCC had victoria blue positive hepatocytes or p53 positive carcinoma cells. These results suggest that there is some difference in the mechanism of carcinogenesis between Theorotrast associated and non-Thorotrast associated HCC.
|
